A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MORPHEUS- CRC)
Study of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Colorectal Cancer (MORPHEUS - CRC)
Sponsor: F. Hoffmann- La Roche Ltd
Enrolling: Male and Female Patients
IRB Number: AAAR5838
U.S. Govt. ID: NCT03555149
Contact: Matthew Ingham, MD: 212-305-5098 / mi2337@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy combination treatments (CIT) combinations versus standard treatment on you and your colorectal cancer (metastatic colorectal cancer - mCRC) to find out which is better
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have metastatic colorectal cancer (mCRC)? Yes No
Did you have disease progression during or following two separate lines of treatment for mCRC? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Matthew Ingham, MD
mi2337@cumc.columbia.edu
212-305-5098
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE